Mankind Pharma, a global pharma company that manufactures and markets a broad range of healthcare products, launches anti-hypertensive-drug Zolahart (Azilsartan).
Aiming at reducing the most commonly related disease of hypertension, the introduction of Zolahart (Azilsartan) at 51 per cent less price (Rs. 7.50 per tablet), is done with the mission of achieving the prime objective of – world class quality at most affordable price.
Azilsartan, a new generation anti-hypertensive drug, offers potent and persistent 24 hours’ blood pressure control. It is proven to be safe for hypertensive patients with comorbid conditions like diabetes or chronic kidney disease (CKD). The recently launched angiotensin-receptor-blocker (Azilsartan) is the most potent amongst ARBs and is expected to reduce the proportion of patients of uncontrolled BP considerably.
Research by the World Health Organization (WHO), shows that hypertension is one of the leading causes of premature deaths in India. It also exerts substantial public health burden on the cardiovascular health status of India.
Speaking on the development, R C Juneja, chairman and founder, Mankind Group said “At Mankind, we endeavour to bring the latest innovative therapies with assured quality that address primary healthcare challenge in India – world class quality at an affordable price. It is with this thought, we decided to launch Zolahart (Azilsartan), the latest anti-hypertensive drug at the most affordable price of Rs. 7.50/-tab” which is 51 per cent less than other competitors.
Inspired by Pradhan Mantri Jan Aushadi Scheme to deliver pharmaceuticals products at affordable price, Mankind Pharma with its Make in India approach has set up goals to sustain a balance in the healthcare of the country.